Summary: The Supreme Court is expected to rule Wednesday on requests from the Biden administration and Danco Laboratories to block a Texas federal judge’s ruling suspending the FDA’s 2000 approval of mifepristone, one of two drugs taken together to end early-stage pregnancies. The following Duke Law experts are available to comment on the challenge to the FDA’s approval and the implications of the court’s ruling.
Jolynn Dellinger is a senior lecturing fellow at Duke Law, where she teaches privacy law and policy, and a Kenan Senior Fellow at the Kenan Institute for Ethics. Dellinger teaches and speaks about the extensive consequences of the Dobbs decision and how criminalizing abortion affects privacy, surveillance and access to reproductive health care.
Arti Rai is the Elvin R. Latty Professor of Law and faculty director of the Center for Innovation Policy at Duke Law School. She is an expert in intellectual property law, innovation policy, administrative law and health law. In 2021 Rai served as a senior adviser on innovation law and policy issues to the Department of Commerce’s Office of General Counsel. She also regularly advises other federal and state agencies as well as Congress on these issues. Rai is a member of the National Academies’ Forum on Drug Discovery, Development, and Translation.
_ _ _ _
Duke experts on a variety of topics can be found here.
Follow Duke News on Twitter: @DukeNews